Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2013 (2013), Article ID 178346, 10 pages
http://dx.doi.org/10.1155/2013/178346
Research Article

Comparison of the Direct Effects of Human Adipose- and Bone-Marrow-Derived Stem Cells on Postischemic Cardiomyoblasts in an In Vitro Simulated Ischemia-Reperfusion Model

1Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Tűzoltó Utca 37-47, Budapest 1094, Hungary
2Department of Anatomy and Experimental Morphology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

Received 1 April 2013; Accepted 31 May 2013

Academic Editor: Shinsuke Yuasa

Copyright © 2013 Mónika Szepes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Regenerative therapies hold a promising and exciting future for the cure of yet untreatable diseases, and mesenchymal stem cells are in the forefront of this approach. However, the relative efficacy and the mechanism of action of different types of mesenchymal stem cells are still incompletely understood. We aimed to evaluate the effects of human adipose- (hASC) and bone-marrow-derived stem cells (hBMSCs) and adipose-derived stem cell conditioned media (ACM) on the viability of cardiomyoblasts in an in vitro ischemia-reperfusion (I-R) model. Flow cytometric viability analysis revealed that both cell treatments led to similarly increased percentages of living cells, while treatment with ACM did not (I-R model: %; hASC: %; hBMSC: %; ACM: %). Metabolic activity measurement (I-R model: ; hASC: ; hBMSC: ; ACM: ; arbitrary units) and lactate dehydrogenase assay (I-R model: ; hASC: ; hBMSC: ; ACM: ; arbitrary units) confirmed the flow cytometric results while also indicated a slight beneficial effect of ACM. Our results highlight that mesenchymal stem cells have the same efficacy when used directly on postischemic cells, and differences found between them in preclinical and clinical investigations are rather related to other possible causes such as their immunomodulatory or angiogenic properties.